Assessment of Patient Frailty Prior to Thoracic Surgery: A Feasibility Study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Lung Cancer
- Sponsor
- University Health Network, Toronto
- Enrollment
- 40
- Locations
- 3
- Primary Endpoint
- Feasibility Assessment
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
Determine the feasibility of assessment of measures of frailty and determine if these measures provide a clinically important contribution of risk assessment in a population of patients undergoing major thoracic surgery for lung or esophageal cancer.
Detailed Description
Both gastro-esophageal and lung cancers are major causes of morbidity and mortality worldwide. In Canada the incidence for Esophageal Adenocarcinoma has doubled in the last two decades, while lung cancer is the leading cause of cancer death. Surgery is a treatment option for these patients; however, esophagectomy in particular, is associated with significant morbidity, mortality and adverse effect on quality of life. Despite satisfactory standard preoperative testing to evaluate risk for surgery, some patients experience morbidity and never recover fully from surgery. Frailty assessment may offer a more sensitive measure of a patient's physiologic reserve, which may allow identification of patients who are poor candidates for surgery. There is a lack of consensus of how best to assess frailty prior to surgery. This study aims to analyze frailty assessment as a tool for patient selection for surgery.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with Esophageal or Lung Cancer who will undergo resectional surgery.
Exclusion Criteria
- •Patients undergoing diagnostic or staging procedures or pulmonary wedge excisions will be excluded.
- •Patients unable to give informed consent
Outcomes
Primary Outcomes
Feasibility Assessment
Time Frame: 2 years
Determine the feasibility of assessment of measures of frailty and determine if these measures provide a clinically important contribution of risk assessment in a population of patients undergoing major thoracic surgery for lung or esophageal cancer.